Drug and Alcohol Review · 2003 · 20 citations · 7 references
PharmacyPharmacotherapySurgeryParenteral Dosage FormsParenteral Drug DeliveryPrescription DispensingInjection SafetyIntravenous Drug DeliveryParenteral FormulationsParenteral PreparationsParenteral Route Of AdministrationSafe Injection PracticesBuprenorphine DispensingBuprenorphine TreatmentIntravenous Injection SafetyParenteral Drug AdministrationParenteral Medication AdministrationParenteral Opioid TherapySkin Graft FailureSublingual Tablets
In May 2002 Buprenorphine (Subutex) was listed on the Australian Pharmaceutical Benefits Schedule for treatment in opioid dependence. In addition to broadening treatment options, buprenorphine has the advantage of an improved safety profile. The risk of overdose is lessened but other risks remain due to diversion. French experience reports widespread deviation of buprenorphine sublingual tablets to intravenous injection. We report a case of attempted parenteral administration of buprenorphine tablets. Stringent protocols for dispensing are appropriate.
7
A Controlled Trial of Buprenorphine Treatment for Opioid Dependence
Rolley E. Johnson · JAMA · 1992 · 565 citations
Injecting misuse of buprenorphine among French drug users
Yolande Obadia, V. Perrin, Isabelle Feroni et al. · Addiction · 2001 · 171 citations
Cases of buprenorphine abuse in India
Rupneet Singh, S. K. Mattoo, Anil K. Malhotra et al. · Acta Psychiatrica Scandinavica · 1992 · 67 citations